PamGene — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PamGene is a private, Netherlands-based proteomics company with a proprietary technology platform for high-throughput, functional kinome profiling. Its core offering enables the simultaneous measurement of kinase activity in biological samples, providing a systems biology view of signaling pathways relevant to cancer and other diseases. The company operates on a platform and services business model, catering to pharmaceutical and biotech partners for drug discovery/optimization and to diagnostic developers for biomarker discovery and patient stratification, particularly in immuno-oncology. PamGene is positioned as a revenue-generating technology enabler in the growing fields of precision medicine and targeted kinase inhibitor development.

Oncology

Technology Platform

Proprietary multiplex, functional kinase activity profiling technology using porous microarrays (PamChip) for real-time, high-throughput measurement of kinome-wide signaling network activity in biological samples.

Funding History

2

GrantUndisclosedEuropean UnionJun 15, 2005

SeedUndisclosedUndisclosedJun 15, 2000

Opportunities

The global shift towards precision medicine and biomarker-driven drug development creates strong demand for functional proteomics tools.

The complexity of cancer therapy resistance, especially in immuno-oncology, presents a specific high-value application for kinome profiling to stratify patients and understand mechanisms.

Expansion into non-oncology diseases driven by kinase signaling (e.g., inflammatory, neurological) offers new market verticals.

Risk Factors

Faces competition from other kinase profiling technologies like mass spectrometry-based phosphoproteomics.

Growth is dependent on securing and maintaining partnerships with pharmaceutical and diagnostic companies, making it vulnerable to shifts in partner priorities.

As a private company, it may have limited capital for aggressive R&D or commercial expansion compared to larger public competitors.

Competitive Landscape

PamGene competes in the functional proteomics and kinase analysis space. Direct competitors include companies offering phospho-antibody arrays and service providers using mass spectrometry for phosphoproteomics. Its key competitive advantage is the real-time, functional kinetic data from its microarray platform, positioned against more static or computationally complex methods. It also competes for budget and attention against broader multi-omics profiling approaches.

More companies in Diagnostics & Precision Medicine →More companies in Netherlands →